medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Number 4

<< Back Next >>

Rev Invest Clin 2010; 62 (4)

The metabolic syndrome, diabetes, and Alzheimer’s disease

García-Lara JMA, Aguilar-Navarro S, Gutiérrez-Robledo LM, Ávila-Funes JA

Language: English
References: 41
Page: 343-349
PDF size: 66.58 Kb.


ABSTRACT

Background. The metabolic syndrome (MS) is a cluster of metabolic abnormalities that has been controversially associated with Alzheimer’s disease (AD), so the purpose of this report was to investigate the association between these two chronic diseases a sample of older persons. Methods. Casecontrol study of 90 consecutive outpatients with AD and 180 non-demented controls from a dementia clinic at a tertiary care hospital in Mexico City. Probable or possible AD was diagnosed according to the guidelines of the Consortium to Establish a Registry for Alzheimer’s Disease, whereas control participants where those classified as normal by the same instrument. MS was defined according to the World Health Organization criteria. Patients were matched 1:2 by age, sex, and years of education. Conditional regression analysis was used to test the association between MS and AD. Results. Compared to controls, MS was more frequent among AD patients (72.2% vs. 23.3%; P ‹ 0.01). While all components of MS were more frequent among cases than control patients, only diabetes was statistically significant, whereas hypertriglyceridemia and low HDL cholesterol were marginally associated. Conditional regression analysis showed that among AD participants, the probability of having MS was about sevenfold higher than for their non-demented counterparts (OR 6.72, 95% CI 3.72-12.13; P ‹ 0.01). Conclusions. The MS is a clinical entity that encompasses a diverse range of chronic diseases, which could be a better risk indicator than any individual MS component for adverse health outcomes, like AD. Our findings underscore the harmful role of MS in the health status of the elderly.


REFERENCES

  1. Yaari R, Corey-Bloom J. Alzheimer’s disease. Semin Neurol 2007: 27; 32-41.

  2. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008: 7; 812-26.

  3. Cummings JL. Alzheimer’s disease. N Engl J Med 2004; 351: 56-67.

  4. Nelson NW. Differential diagnosis of Alzheimer’s dementia and vascular dementia. Dis Mon 2007; 53: 148-51.

  5. Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153-60.

  6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.

  7. Whelan DM, Roy RC. Diseases of aging that emerge from the metabolic syndrome. Anesthesiol Clin 2006; 24: 599-619.

  8. Kudo T, Imaizumi K, Tanimukai H, et al. Are cerebrovascular factors involved in Alzheimer’s disease? Neurobiol Aging 2000; 21: 215-24.

  9. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  10. Villalpando-Berumen JM, Mejia-Arango S, Aguilar-Salinas CA, et al. Apolipoprotein E epsilon4, Alzheimer’s disease, and cognitive performance in elderly Mexican Mestizos. J Am Geriatr Soc 2008; 56: 677-82.

  11. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.

  12. Morris JC. Clinical assessment of Alzheimer’s disease. Neurology 1997; 49: 7-10.

  13. Welsh-Bohmer KA, Mohs RC. Neuropsychological assessment of Alzheimer’s disease. Neurology 1997; 49: 11-3.

  14. Mirra SS. Neuropathological assessment of Alzheimer’s disease: the experience of the Consortium to Establish a Registry for Alzheimer’s Disease. Int Psychogeriatr 1997; 9(Suppl. 1): 263-8.

  15. Buckholtz N. Background and purpose of the Consortium to Establish a Registry for Alzheimer’s Disease. Neurology 1997; 49(Suppl. 3): S1.

  16. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. The metabolic syndrome: a concept hard to define. Arch Med Res 2005; 36: 223-31.

  17. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.

  18. Yaffe K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res 2007; 4: 123-6.

  19. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.

  20. Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-51.

  21. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-7.

  22. Zhu X, Lee HG, Perry G, et al. Alzheimer disease, the twohit hypothesis: an update. Biochim Biophys Acta 2007; 1772: 494-502.

  23. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002; 1: 61-77.

  24. van den Berg E, Biessels GJ, de Craen AJ, et al. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69: 979-85.

  25. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006; 20: 298-301.

  26. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.

  27. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-81.

  28. Kraja AT, Rao DC, Weder AB, et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab (Lond) 2005; 2: 17.

  29. Seux ML, Staessen JA, Forette F. [Treatment of isolated systolic arterial hypertension and prevention of dementia in aged patients. The Syst-Eur multicenter study]. Arch Mal Coeur Vaiss 1999; 92: 1083-7.

  30. Moretti R, Torre P, Antonello RM, et al. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag 2008; 4: 395-402.

  31. Zhu X, Smith MA, Honda K, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007; 257: 240-6.

  32. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.

  33. Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 2006; 22: 173-6.

  34. Chiang CJ, Yip PK, Wu SC, et al. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry 2007; 15: 762-71.

  35. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64: 1689-95.

  36. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42: 776-82.

  37. West NA, Haan MN, Morgenstern H. The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study. Neurobiol Aging 2008; 16: 2008e.

  38. Canizales-Quinteros S, Aguilar-Salinas CA, Ortiz-Lopez MG, et al. Association of PPARG2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Hum Biol 2007; 79: 111-9.

  39. Quin W, Haroutunian V, Katsel P, et al.PGC-1α expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66: 352-61.

  40. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord 2007; 21: 167-71.

  41. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. [The metabolic syndrome: a concept in evolution]. Gac Med Mex 2004; 140(Suppl. 2): 41-8.




2020     |     www.medigraphic.com